Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 2:50 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2905–2928 of 13,638 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Dermatologic Disorders Clear all

Conditions: Breast Cancer
Interventions: CyberKnife Stereotactic Accelerated Partial Breast Irradiation (CK-SAPBI); Radiation
Lead sponsor: Georgetown University; Other
Eligibility: 50 Years to 99 Years · Female only
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Basal Cell Carcinoma
Interventions: Not listed
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 115 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 2
States / cities: Chicago, Illinois • Naperville, Illinois

Conditions: Diamond Blackfan Anemia, Dyskeratosis Congenita, Fanconi Anemia, Shwachman Diamond Syndrome, Inherited Bone Marrow Failure Syndrome, Aplastic Anemia
Interventions: Not listed
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 1 Day to 100 Years
Enrollment: 4,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2001
U.S. locations: 2
States / cities: Bethesda, Maryland • Rockville, Maryland

Conditions: Breast Cancer
Interventions: Phase II - Preoperative Radiation followed by Lumpectomy.; Radiation
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 40 Years and older · Female only
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2027
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Breast Cancer, Lung Cancer, Genito-Urinary Cancer, Colorectal Cancer, Gastric Cancer, Pancreatic Cancer, Liver Cancer, Head and Neck Cancer, Melanoma
Interventions: Hello for Cancer game, Table Topics game; Behavioral · Other
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Hershey, Pennsylvania

Conditions: Breast Cancer
Interventions: PF-07220060, letrozole; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 10
States / cities: Barrington, Illinois • Crystal Lake, Illinois • Park Ridge, Illinois + 2 more

Conditions: Breast Cancer, Breast Neoplasm, Breast Tumor, Cancer of the Breast
Interventions: Proton Radiotherapy; Radiation
Lead sponsor: Proton Collaborative Group; Network
Eligibility: 50 Years and older · Female only
Enrollment: 132 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2035
U.S. locations: 9
States / cities: Scottsdale, Arizona • San Diego, California • Warrenville, Illinois + 6 more

Conditions: Breast Neoplasms, Breast Cancer
Interventions: Patritumab deruxtecan, Pembrolizumab, Paclitaxel, Carboplatin, Doxorubicin hydrochloride, Epirubicin hydrochloride, Cyclophosphamide, Capecitabine, Olaparib; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 372 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 8
States / cities: Santa Monica, California • Skokie, Illinois • Billings, Montana + 5 more

Conditions: Metastatic Melanoma, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7
Interventions: Aldesleukin, Cyclophosphamide, Fludarabine Phosphate, Laboratory Biomarker Analysis, Pembrolizumab, Quality-of-Life Assessment, Therapeutic Tumor Infiltrating Lymphocytes; Biological · Drug · Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2022
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Chronic Ulcer of Leg or Foot, Pressure Injury
Interventions: ConvaFoam; Device
Lead sponsor: ConvaTec Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 95 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 5
States / cities: Hagerstown, Maryland • Mineola, New York • Raleigh, North Carolina + 2 more

Conditions: Hidradenitis Suppurativa
Interventions: Ritlecitinib, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 128 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 30
States / cities: Hot Springs, Arkansas • Fountain Valley, California • Northridge, California + 22 more

Conditions: Rosacea
Interventions: Imipramine, Amitriptyline, Vehicle; Drug
Lead sponsor: Wright State University; Other
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Fairborn, Ohio

Conditions: Behçet's Syndrome
Interventions: Apremilast, Placebo; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older
Enrollment: 207 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 11
States / cities: Phoenix, Arizona • Sacramento, California • Ormond Beach, Florida + 8 more

Conditions: Cutaneous Lupus Erythematosus (CLE), Systematic Lupus Erythematosus
Interventions: Afimetoran, Placebo; Drug
Lead sponsor: Beeline Medicines Corporation; Industry
Eligibility: 16 Years and older
Enrollment: 390 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 3
States / cities: San Diego, California • DeBary, Florida • Missoula, Montana

Conditions: Colon Cancer, Breast Cancer, Cervical Cancer, Prostate Cancer, Cardiovascular Disease
Interventions: Community vital signs; Other
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 18 Years to 99 Years
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 2
States / cities: Fairfax, Virginia • Richmond, Virginia

Conditions: Venous Leg Ulcer (VLU)
Interventions: Topical Wound Oxygen Therapy, Sham Control Topical Wound Oxygen; Device
Lead sponsor: AOTI Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 212 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: New York, New York

Conditions: Recurrent Breast Carcinoma, Stage IV Breast Cancer
Interventions: Gemcitabine Hydrochloride, Tipifarnib, Laboratory Biomarker Analysis; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Breast Cancer
Interventions: Ipatasertib, Fulvestrant, Aromatase Inhibitor, Palbociclib; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older · Female only
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Porphyria Cutanea Tarda, Hepatitis C
Interventions: Harvoni; Drug
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 3
States / cities: San Francisco, California • Winston-Salem, North Carolina • Galveston, Texas

Conditions: Hidradenitis Suppurativa
Interventions: LOU064, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 2
States / cities: San Diego, California • Mayfield Heights, Ohio

Conditions: Breast Cancer, Drug/Agent Toxicity by Tissue/Organ
Interventions: amifostine trihydrate, cyclophosphamide, mitoxantrone hydrochloride, thiotepa, peripheral blood stem cell transplantation; Drug · Procedure
Lead sponsor: University of Arizona; Other
Eligibility: 16 Years to 70 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2002
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Cancer
Interventions: palivizumab, ribavirin; Biological · Drug
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: Not listed
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2001
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Melanoma
Interventions: GM-CSF-in-adjuvant, Montanide ISA-51, GM-CSF and Montanide ISA-51, Saline; Drug · Biological
Lead sponsor: University of Virginia; Other
Eligibility: 18 Years to 85 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2004
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Melanoma (Skin)
Interventions: aldesleukin, recombinant fowlpox-tyrosinase vaccine, vaccinia-tyrosinase vaccine; Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 16 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 1
States / cities: Bethesda, Maryland

Search by objective public record fields.

A Multi-Institutional Registry for CyberKnife Stereotactic Accelerated Partial Breast Irradiation (CK-SAPBI)

Basal Cell Carcinoma Recurrence After Mohs Surgery

Cancer in Inherited Bone Marrow Failure Syndromes

MRI-Based Preoperative Accelerated Partial Breast Irradiation

Using an End-of-life Conversation Game to Engage Patients With Cancer in Advance Care Planning: Phase 2

A Study to Learn About the Study Medicine PF-07220060 Together With Letrozole Compared to Letrozole Alone in Women Post Menopause

Phase II Protocol of Proton Therapy for Partial Breast Irradiation in Early Stage Breast Cancer

Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)

Pembrolizumab, Standard Chemotherapy, Tumor Infiltrating Lymphocytes, and High- or Low-Dose Aldesleukin in Treating Patients With Metastatic Melanoma

A Prospective, Multi Centre, Interventional, Non-comparator, Open Label Study to Demonstrate the Efficacy, Safety, and Performance of ConvaFoam™ Dressings in the Management of Indicated Chronic Wound Types.

A 16-Week Study to Learn About the Study Medicine Called Ritlecitinib in Adults With Long Lasting Painful Red Skin Lumps, Known by the Medical Term, Hidradenitis Suppurativa, or HS.

Evaluating Use of Topical Imipramine and Amitriptyline in Reducing Ultraviolet B Light-Induced Redness in Patients With Rosacea

A Phase 3 Randomized, Double-blind Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in Subjects With Active Behçet's Disease

Study of Afimetoran in Adults With Cutaneous Lupus Erythematosus

Understanding the Value of Community Vital Signs in Primary Care

Trial to Evaluate Cyclical Topical Wound Oxygen Therapy in the Treatment of Chronic Venous Leg Ulcers

Tipifarnib and Gemcitabine Hydrochloride in Treating Women With Metastatic Breast Cancer

AKT Inhibitor, Ipatasertib, With Endocrine and CDK 4/6 Inhibitor for Patients With Metastatic Breast Cancer (TAKTIC)

Harvoni Treatment Porphyria Cutanea Tarda

A Study to Explore the Tissue Level Effects of Remibrutinib in Adults With Moderate to Severe HS

High-Dose Chemotherapy and Autologous Blood Cell Transplantation in Treating Patients With Primary, Locally Advanced, or Stage IV Breast Cancer

Ribavirin With or Without Monoclonal Antibody Therapy in Treating Patients Who Develop RSV Pneumonia Following Peripheral Stem Cell Transplantation

Evaluation of the Effects of Local Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in Adjuvant Administration on Dendritic Cells in Skin of Melanoma Patients and in Sentinel Lymph Nodes: MEL38

Vaccine Therapy and Interleukin-2 in Treating Patients With Metastatic Melanoma